Davidson Investment Advisors Acquires 185,733 Shares of Pfizer Inc. $PFE

Davidson Investment Advisors raised its holdings in Pfizer Inc. (NYSE:PFE) by 45.2% during the second quarter, Holdings Channel.com reports. The fund owned 596,252 shares of the biopharmaceutical company’s stock after purchasing an additional 185,733 shares during the period. Davidson Investment Advisors’ holdings in Pfizer were worth $14,453,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter valued at approximately $27,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter worth $28,000. North Capital Inc. bought a new position in shares of Pfizer during the first quarter worth $28,000. WPG Advisers LLC bought a new position in shares of Pfizer during the first quarter worth $35,000. Finally, Horizon Financial Services LLC bought a new position in shares of Pfizer during the first quarter worth $35,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 0.5%

Shares of NYSE:PFE opened at $24.39 on Thursday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.82. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company’s fifty day simple moving average is $24.89 and its 200 day simple moving average is $24.13. The firm has a market cap of $138.69 billion, a price-to-earnings ratio of 12.98, a PEG ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the business posted $0.60 earnings per share. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Analyst Ratings Changes

PFE has been the topic of a number of recent analyst reports. Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Finally, Morgan Stanley reduced their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.